Skip to content
The Policy VaultThe Policy Vault

Viberzi (eluxadoline) — Point32Health

Irritable bowel syndrome with diarrhea (IBS-D)

Initial criteria

  • The patient has a diagnosis of irritable bowel syndrome with diarrhea (IBS-D)

Reauthorization criteria

  • Documentation of a positive clinical response to therapy

Approval duration

initial 6 months; subsequent life of plan